Adhera Therapeutics, Inc. (ATRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -1.61 Million USD | -140.06% |
| 2021 | -674 Thousand USD | 66.91% |
| 2020 | -2.03 Million USD | 82.0% |
| 2019 | -11.31 Million USD | 28.36% |
| 2018 | -15.79 Million USD | -159.33% |
| 2017 | -6.09 Million USD | -703.8% |
| 2016 | -757.73 Thousand USD | 81.0% |
| 2015 | -3.98 Million USD | -13.32% |
| 2014 | -3.52 Million USD | -864.38% |
| 2013 | -365 Thousand USD | 95.37% |
| 2012 | -7.88 Million USD | 77.47% |
| 2011 | -34.99 Million USD | -18.51% |
| 2010 | -29.53 Million USD | -176.16% |
| 2009 | -10.69 Million USD | 81.86% |
| 2008 | -58.94 Million USD | -8.09% |
| 2007 | -54.53 Million USD | -86.0% |
| 2006 | -29.31 Million USD | 13.27% |
| 2005 | -33.8 Million USD | -18.64% |
| 2004 | -28.49 Million USD | -358.72% |
| 2003 | -6.21 Million USD | 54.28% |
| 2002 | -13.58 Million USD | -42.18% |
| 2001 | -9.55 Million USD | 7.56% |
| 2000 | -10.33 Million USD | -8.79% |
| 1999 | -9.5 Million USD | -295.83% |
| 1998 | -2.4 Million USD | 60.0% |
| 1997 | -6 Million USD | 0.0% |
| 1996 | - USD | 100.0% |
| 1995 | -100 Thousand USD | -150.0% |
| 1994 | 200 Thousand USD | 176.92% |
| 1993 | -260 Thousand USD | 49.02% |
| 1992 | -510 Thousand USD | 23.88% |
| 1991 | -670 Thousand USD | -28.85% |
| 1990 | -520 Thousand USD | 16.13% |
| 1989 | -620 Thousand USD | 43.64% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -353 Thousand USD | 2.22% |
| 2023 Q3 | -269.49 Thousand USD | 8.95% |
| 2023 Q2 | -296 Thousand USD | 16.15% |
| 2022 Q4 | -361 Thousand USD | 34.12% |
| 2022 Q1 | -260 Thousand USD | -28.08% |
| 2022 Q2 | -449 Thousand USD | -72.69% |
| 2022 Q3 | -548 Thousand USD | -22.05% |
| 2022 FY | -1.61 Million USD | -140.06% |
| 2021 Q1 | -110 Thousand USD | 32.93% |
| 2021 Q3 | -231 Thousand USD | -79.07% |
| 2021 Q2 | -129 Thousand USD | -17.27% |
| 2021 FY | -674 Thousand USD | 66.91% |
| 2021 Q4 | -203 Thousand USD | 12.12% |
| 2020 Q1 | -1.32 Million USD | 64.77% |
| 2020 FY | -2.03 Million USD | 82.0% |
| 2020 Q2 | -356 Thousand USD | 73.09% |
| 2020 Q3 | -194 Thousand USD | 45.51% |
| 2020 Q4 | -164 Thousand USD | 15.46% |
| 2019 Q1 | -2.55 Million USD | 15.59% |
| 2019 Q3 | -2.22 Million USD | 19.97% |
| 2019 FY | -11.31 Million USD | 28.36% |
| 2019 Q4 | -3.75 Million USD | -68.84% |
| 2019 Q2 | -2.77 Million USD | -8.63% |
| 2018 Q2 | -3.76 Million USD | -209.78% |
| 2018 Q4 | -3.03 Million USD | 61.04% |
| 2018 Q3 | -7.77 Million USD | -106.45% |
| 2018 Q1 | -1.21 Million USD | 61.24% |
| 2018 FY | -15.79 Million USD | -159.33% |
| 2017 Q2 | -948.91 Thousand USD | 1.9% |
| 2017 FY | -6.09 Million USD | -703.8% |
| 2017 Q4 | -3.13 Million USD | -202.94% |
| 2017 Q1 | -967.25 Thousand USD | -184.46% |
| 2017 Q3 | -1.03 Million USD | -9.18% |
| 2016 Q1 | -1 Million USD | -61.45% |
| 2016 Q4 | 1.14 Million USD | 311.7% |
| 2016 Q3 | -541 Thousand USD | -49.86% |
| 2016 FY | -757.73 Thousand USD | 81.0% |
| 2016 Q2 | -361 Thousand USD | 63.94% |
| 2015 Q2 | -1.02 Million USD | 22.28% |
| 2015 FY | -3.98 Million USD | -13.32% |
| 2015 Q3 | -1.03 Million USD | -0.98% |
| 2015 Q1 | -1.31 Million USD | -93.67% |
| 2015 Q4 | -620 Thousand USD | 39.92% |
| 2014 FY | -3.52 Million USD | -864.38% |
| 2014 Q4 | -679 Thousand USD | 57.75% |
| 2014 Q3 | -1.6 Million USD | -139.49% |
| 2014 Q2 | -671 Thousand USD | -19.18% |
| 2014 Q1 | -563 Thousand USD | -2547.83% |
| 2013 Q2 | -186 Thousand USD | 42.94% |
| 2013 FY | -365 Thousand USD | 95.37% |
| 2013 Q4 | 23 Thousand USD | -81.45% |
| 2013 Q3 | 124 Thousand USD | 166.67% |
| 2013 Q1 | -326 Thousand USD | 78.05% |
| 2012 Q1 | -4.18 Million USD | 77.59% |
| 2012 FY | -7.88 Million USD | 77.47% |
| 2012 Q4 | -1.48 Million USD | 12.18% |
| 2012 Q3 | -1.69 Million USD | -220.87% |
| 2012 Q2 | -527 Thousand USD | 87.39% |
| 2011 FY | -34.99 Million USD | -18.51% |
| 2011 Q1 | -5.26 Million USD | 20.1% |
| 2011 Q2 | -5.44 Million USD | -3.46% |
| 2011 Q3 | -5.62 Million USD | -3.23% |
| 2011 Q4 | -18.65 Million USD | -231.63% |
| 2010 Q4 | -6.59 Million USD | 38.88% |
| 2010 Q3 | -10.78 Million USD | -75.33% |
| 2010 Q2 | -6.15 Million USD | -2.53% |
| 2010 FY | -29.53 Million USD | -176.16% |
| 2010 Q1 | -6 Million USD | -15.9% |
| 2009 Q4 | -5.17 Million USD | 24.43% |
| 2009 Q1 | 7.79 Million USD | 163.77% |
| 2009 Q3 | -6.85 Million USD | -6.05% |
| 2009 Q2 | -6.46 Million USD | -182.87% |
| 2009 FY | -10.69 Million USD | 81.86% |
| 2008 Q3 | -15.94 Million USD | -12.05% |
| 2008 Q1 | -16.54 Million USD | -34.41% |
| 2008 FY | -58.94 Million USD | -8.09% |
| 2008 Q2 | -14.22 Million USD | 14.0% |
| 2008 Q4 | -12.22 Million USD | 23.34% |
| 2007 Q4 | -12.31 Million USD | 27.45% |
| 2007 Q3 | -16.96 Million USD | -30.23% |
| 2007 FY | -54.53 Million USD | -86.0% |
| 2007 Q2 | -13.02 Million USD | -6.56% |
| 2007 Q1 | -12.22 Million USD | -10.16% |
| 2006 FY | -29.31 Million USD | 13.27% |
| 2006 Q4 | -11.09 Million USD | -32.15% |
| 2006 Q1 | -8.66 Million USD | 8.61% |
| 2006 Q2 | -1.15 Million USD | 86.7% |
| 2006 Q3 | -8.39 Million USD | -628.36% |
| 2005 FY | -33.8 Million USD | -18.64% |
| 2005 Q3 | -9.24 Million USD | -6.33% |
| 2005 Q4 | -9.48 Million USD | -2.65% |
| 2005 Q2 | -8.69 Million USD | -36.08% |
| 2005 Q1 | -6.38 Million USD | -7.85% |
| 2004 FY | -28.49 Million USD | -358.72% |
| 2004 Q4 | -5.92 Million USD | 21.34% |
| 2004 Q3 | -7.52 Million USD | -1.17% |
| 2004 Q2 | -7.44 Million USD | 2.14% |
| 2004 Q1 | -7.6 Million USD | -28.15% |
| 2003 Q4 | -5.93 Million USD | 5.01% |
| 2003 FY | -6.21 Million USD | 54.28% |
| 2003 Q1 | -2.83 Million USD | 50.26% |
| 2003 Q3 | -6.24 Million USD | -170.98% |
| 2003 Q2 | 8.8 Million USD | 410.73% |
| 2002 Q1 | -2.86 Million USD | 7.44% |
| 2002 Q2 | -1.55 Million USD | 45.75% |
| 2002 Q3 | -3.47 Million USD | -124.1% |
| 2002 Q4 | -5.69 Million USD | -63.71% |
| 2002 FY | -13.58 Million USD | -42.18% |
| 2001 FY | -9.55 Million USD | 7.56% |
| 2001 Q2 | -2.16 Million USD | 2.87% |
| 2001 Q4 | -3.09 Million USD | -63.2% |
| 2001 Q3 | -1.89 Million USD | 12.44% |
| 2001 Q1 | -2.22 Million USD | 39.73% |
| 2000 FY | -10.33 Million USD | -8.79% |
| 2000 Q2 | -2.41 Million USD | -1.77% |
| 2000 Q1 | -2.37 Million USD | 40.63% |
| 2000 Q3 | -1.84 Million USD | 23.54% |
| 2000 Q4 | -3.69 Million USD | -99.95% |
| 1999 Q4 | -4 Million USD | -100.0% |
| 1999 Q1 | -2.4 Million USD | -50.0% |
| 1999 Q2 | -1.7 Million USD | 29.17% |
| 1999 Q3 | -2 Million USD | -17.65% |
| 1999 FY | -9.5 Million USD | -295.83% |
| 1998 Q3 | -600 Thousand USD | -200.0% |
| 1998 Q2 | -200 Thousand USD | 0.0% |
| 1998 Q1 | -200 Thousand USD | 91.67% |
| 1998 Q4 | -1.6 Million USD | -166.67% |
| 1998 FY | -2.4 Million USD | 60.0% |
| 1997 Q3 | -1.7 Million USD | -30.77% |
| 1997 FY | -6 Million USD | 0.0% |
| 1997 Q4 | -2.4 Million USD | -41.18% |
| 1997 Q2 | -1.3 Million USD | -85.71% |
| 1997 Q1 | -700 Thousand USD | 0.0% |
| 1996 Q2 | 200 Thousand USD | 100.0% |
| 1996 Q1 | 100 Thousand USD | 133.33% |
| 1996 Q3 | -100 Thousand USD | -150.0% |
| 1996 FY | - USD | 100.0% |
| 1995 Q2 | -200 Thousand USD | 0.0% |
| 1995 Q1 | - USD | 100.0% |
| 1995 Q3 | -100 Thousand USD | 50.0% |
| 1995 Q4 | -300 Thousand USD | -200.0% |
| 1995 FY | -100 Thousand USD | -150.0% |
| 1994 Q2 | 100 Thousand USD | 200.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 FY | 200 Thousand USD | 176.92% |
| 1994 Q4 | -100 Thousand USD | -200.0% |
| 1994 Q1 | -100 Thousand USD | -200.0% |
| 1993 Q3 | 100 Thousand USD | 300.0% |
| 1993 FY | -260 Thousand USD | 49.02% |
| 1993 Q4 | 100 Thousand USD | 0.0% |
| 1993 Q2 | -50 Thousand USD | 0.0% |
| 1992 FY | -510 Thousand USD | 23.88% |
| 1991 FY | -670 Thousand USD | -28.85% |
| 1990 FY | -520 Thousand USD | 16.13% |
| 1989 FY | -620 Thousand USD | 43.64% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -21.159% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 67.925% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 90.934% |
| Nascent Biotech, Inc. | -2.22 Million USD | 27.44% |
| Rebus Holdings, Inc. | -664 Thousand USD | -143.675% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.977% |
| Qrons Inc. | -643.67 Thousand USD | -151.368% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -315.33% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.085% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -289.43% |
| Skye Bioscience, Inc. | -13.67 Million USD | 88.165% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.746% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 132.921% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -518.204% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.866% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 43.238% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -5.335% |
| Mesoblast Limited | -84.14 Million USD | 98.077% |
| Marizyme, Inc. | -34.08 Million USD | 95.253% |
| Genus plc | 6.4 Million USD | 125.281% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 116.608% |
| Pharming Group N.V. | -4.87 Million USD | 66.841% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 18.549% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -73.721% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 80.623% |
| ContraFect Corporation | -56.88 Million USD | 97.156% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 64.476% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -15.407% |
| IMV Inc. | -38.67 Million USD | 95.816% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 41.182% |
| MultiCell Technologies, Inc. | -722.81 USD | -223748.591% |
| ONE Bio Corp. | 13.68 Million USD | 111.826% |
| Accustem Sciences Inc. | -3.74 Million USD | 56.812% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.257% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -234.947% |
| Q BioMed Inc. | -3.44 Million USD | 53.042% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 145.706% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 38.421% |
| Biomind Labs Inc. | -1 Million USD | -60.261% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.057% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 44.231% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 75.662% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 13.215% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -5301.976% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 89.804% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 16.279% |
| GB Sciences, Inc. | -1.42 Million USD | -13.903% |
| Alpha Cognition Inc. | -9.7 Million USD | 83.329% |
| HST Global, Inc. | -140.9 Thousand USD | -1048.275% |
| CSL Limited | 3.7 Billion USD | 100.044% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -43.834% |
| Halberd Corporation | -75.05 Thousand USD | -2055.896% |
| Enzolytics Inc. | -2.14 Million USD | 24.702% |
| Agentix Corp. | -1.37 Million USD | -17.951% |
| Resverlogix Corp. | -12.74 Million USD | 87.309% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 48.931% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.619% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -54.981% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 44.578% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -2.447% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 52.481% |
| AVAX Technologies, Inc. | 6.69 Million USD | 124.175% |
| Zenith Capital Corp. | -8.94 Million USD | 81.908% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.611% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -9187.641% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 34.102% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -843.388% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 19.292% |
| Kadimastem Ltd | -3.04 Million USD | 46.781% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -64.422% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -28.822% |
| BioStem Technologies, Inc. | -7.77 Million USD | 79.2% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -791.534% |
| LadRx Corporation | -3.82 Million USD | 57.684% |
| Cell Source, Inc. | -4.32 Million USD | 62.593% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -135.534% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -135.534% |
| NovAccess Global Inc. | -2.46 Million USD | 34.408% |
| Affymax, Inc. | -15.04 Million USD | 89.246% |
| Itoco Inc. | -919.14 Thousand USD | -76.034% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 61.825% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -44.593% |
| Mobile Lads Corp. | -554.55 Thousand USD | -191.768% |
| CytoDyn Inc. | -18.05 Million USD | 91.04% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -6328.288% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -635.194% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -186.512% |
| SYBLEU INC | -149.18 Thousand USD | -984.596% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 10.919% |
| International Stem Cell Corporation | -663 Thousand USD | -144.042% |
| Bioxytran, Inc. | -3.82 Million USD | 57.646% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2973.708% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -7854.769% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 95.539% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -119.886% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 47.991% |
| Neutra Corp. | -229.48 Thousand USD | -605.054% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 90.775% |
| PureTech Health plc | -146.19 Million USD | 98.893% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 92.471% |
| IXICO plc | -1.43 Million USD | -12.596% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 82.952% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.672% |
| CSL Limited | 3.81 Billion USD | 100.042% |
| Cellectis S.A. | -108.85 Million USD | 98.514% |